[12] Patent
[11] Patent No.:GC0011526  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2020                77/2020  
Number of the Decision to Grant the Patent:2020/176284
Date of the Decision to Grant the Patent:09/Dec/2020

[21] Application No.:GC 2018-35024

[22] Filing Date:26/3/2018

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
11/4/2017
62/484,025

[72] Inventors:1- Igor Edmondo Paolo D'ANGELO،2- Yiwen LI،3- Dale Lincoln LUDWIG،4- Yang SHEN،5- Yi ZHANG

[73] Owners:1- Eli Lilly And Company, Lilly Corporate Center, Indiana 46206-6288, USA, Indianapolis, USA،2- Zymeworks, Inc., 540-1385West 8th Avenue, Vancouver British Columbia, V6H 3V9, Canada, Columbia, Canada

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 39/395, 39/40, 45/06, 9/00; A61P 35/00; C07K 16/12, 16/26, 16/28, 16/36, 16/46; C12P 21/00 (2006.01)

[56] Cited Documents:

-WO 2017/034916 Al (LILLY CO ELI [US])2 March 2017
-WO 2015/048312 Al (COSTIM PHARMACEUTICALSINC [US]; WISCONSIN MED COLLEGE INC [US])2 April 2015
-WO 2016/061142 Al (NOVARTIS AG [CH]; DANAFARBER CANCER INST INC [US]; HARVARDCOLLEGE [U) 21 April 2016
-WO 2014/055897 A2 (DANA FARBER CANCER INSTINC [US]) 10 April 2014
-US 2018/057591 Al (ZHANG YI [US] ET AL)1 March 2018
 
Examiner: Hanien H Al Ghannami

[54] ANTI-PD-L1-ANTI-TIM-3 BISPECIFIC ANTIBODIES
[57] Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
No. of claims: 21


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.